Curaleaf Holdings has increased its hostile takeover offer for Aurora Cannabis to $5 per share, escalating what has become one of the most closely watched M&A battles in the cannabis industry.
The revised bid from the Massachusetts-based multistate operator comes after Aurora's board rejected Curaleaf's initial offer earlier this year. Curaleaf says it built the $5-per-share proposal using publicly available data and argues Aurora shareholders deserve a transparent process if the company's board allows other potential buyers access to due diligence materials.
The move marks a significant moment in cross-border cannabis consolidation. Aurora, once valued at over $12 billion during the 2018 cannabis bubble, has seen its market cap shrink dramatically. The Edmonton-based producer has struggled with profitability despite being one of Canada's largest licensed cultivators.
The Numbers
At $5 per share, Curaleaf's offer values Aurora at roughly $1.2 billion based on current outstanding shares. That represents a premium over Aurora's recent trading range but falls well below the company's peak valuations from 2018-2019.
Curaleaf operates 152 retail dispensaries across 18 U.S. states and generated $1.4 billion in revenue last year. The company has positioned itself as a consolidator in the fragmented American cannabis market, though this would mark its first major international acquisition.
Aurora reported $255 million in net revenue for its most recent fiscal year. The company has undergone multiple restructurings and asset sales as it attempts to reach sustained profitability in Canada's oversupplied recreational market.
Why Now
The timing reflects broader industry dynamics. Canadian licensed producers have faced years of financial pressure from oversupply, price compression, and limited international expansion opportunities. Meanwhile, U.S. operators like Curaleaf have built substantial cash reserves but face federal prohibition that limits traditional growth strategies.
Curaleaf's hostile approach suggests the company sees strategic value in Aurora's cultivation infrastructure, international medical cannabis partnerships, and potential future access to Canadian adult-use distribution. Aurora maintains medical cannabis operations in Germany, Australia, and several other international markets.
But the acquisition faces regulatory hurdles. Canadian foreign investment rules require government approval for takeovers of significant domestic companies. And Curaleaf would need to navigate the complexities of owning assets in both U.S. state-legal markets and federally legal international jurisdictions.
What Aurora Says
Aurora's board has not yet publicly responded to the increased offer. The company's management has previously emphasized its focus on achieving profitability through operational efficiency rather than pursuing a sale.
Industry analysts note that Aurora's board has a fiduciary duty to consider legitimate offers that provide shareholder value. If Curaleaf can demonstrate financing and regulatory feasibility, Aurora may face pressure from institutional investors to negotiate.
Industry Response
The attempted takeover has sparked debate about valuation gaps between Canadian and U.S. cannabis companies. Several Canadian LPs trade at significant discounts to their U.S. counterparts despite operating in federally legal frameworks.
Some analysts view the bid as opportunistic, taking advantage of Aurora's depressed stock price. Others see it as recognition that Canadian cultivation expertise and international licensing could prove valuable as global cannabis markets mature.
The outcome could influence other cross-border M&A discussions. Several U.S. MSOs have explored Canadian LP acquisitions as potential pathways to international expansion and NASDAQ uplisting opportunities if U.S. federal reform advances.
What's Next
Curaleaf has indicated it built the $5-per-share offer without access to Aurora's non-public financial data. The company argues that if Aurora's board provides due diligence access to other potential acquirers, Curaleaf should receive the same treatment to ensure a fair process for shareholders.
Aurora's board will need to respond formally to the revised offer. The company could reject it again, open negotiations, or run a formal sale process inviting competing bids. Shareholders may also pressure the board to engage if they view $5 per share as attractive relative to Aurora's standalone prospects.
The cannabis M&A market has seen limited major deals in 2024 amid ongoing capital constraints and regulatory uncertainty. This attempted takeover represents one of the year's most significant proposed transactions by dollar value.
This article is based on original reporting by mjbizdaily.com.
